Advertisement

Receptors for thromboxane and prostaglandins

  • R. L. Jones
  • N. H. Wilson
  • R. A. Armstrong
  • Y. J. Dong
Chapter

Abstract

The elucidation of the structures of thomboxane A2 and prostaglandin D2, E2, F2a and I2, all products of the cyclic endoperoxides PGG2/PGH2, was accompanied by the demonstration of a distinctive biological profile for each compound. Stimulant or inhibitory activity was often observed at nanomolar concentrations. To the pharmacologist these findings indicate the probable existence of separate cellular receptors. This manuscript describes attempts by ourselves and other research groups to substantiate this hypothesis by obtaining data from four experimental strategies; ranking of agonist potencies, the use of specific antagonists, desensitisation of receptor systems, and ligand binding measurements.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. ALPHEN, G.W.H.M. & ANGEL, M.A. (1975). Activity of prostaglandins E, F, and B, on sphincter, dilator and ciliary muscle of the cat eye. Prostaglandins, 9, 157–166.CrossRefGoogle Scholar
  2. ARMSTRONG, R.A., JONES, R.L. & WILSON, N.H. (1983). Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br. J. Pharmac, 79, 953–964.CrossRefGoogle Scholar
  3. BENNETT, A. (1974). Prostaglandin antagonists. In Advances in Drug Research, Vol. 8. Harper, N.J. & Sim-monds, A.B. (eds) pp. 83–118, London: Academic Press.Google Scholar
  4. BENNETT, A. & POSNER, J. (1971). Studies on prostaglandin antagonists. Br. J. Pharmac, 42, 584–594.CrossRefGoogle Scholar
  5. BLAIR, I.A. & MacDERMOT, J. (1981). The binding of [3H]-prostacyclin to membranes of a neuronal somatic hybrid. Br. J. Pharmac, 72, 435–441.CrossRefGoogle Scholar
  6. BORN, G.V.R. (1962). Quantitative investigations into the aggregation of blood platelets. J. Physiol., 162, 67P.Google Scholar
  7. CASALS-STENZEL, J., BUSE, M. & LOSERT, W. (1983). Comparison of the vasodepressor action of ZK 36374, a stable prostacyclin derivative, PGI2 and PGEj with their effect on platelet aggregation and bleeding time in rats. Prostaglandins, Leukotrienes Med., 10, 197–212.CrossRefGoogle Scholar
  8. COLEMAN, R.A., HUMPHREY, P.P.A., KENNEDY, I., LEVY, G.P. & LUMLEY, P. (1981). Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br. J. Pharmac., 73, 773–778.CrossRefGoogle Scholar
  9. DONG, Y.J. & JONES, R.L. (1982). Effects of prostaglandins and thromboxane analogues on bullock and dog iris sphincter preparations. Br. J. Pharmac, 76, 149–155.CrossRefGoogle Scholar
  10. DUKES, M., RUSSELL, W. & WALPOLE, A.L. (1974). The synthesis and biological activity of potent selective luteolytic prostaglandins. Nature, 250, 330–331.CrossRefGoogle Scholar
  11. HAMMARSTRÖM, S. (1982). A receptor for prostaglandin F2a from corpora lutea. In Methods in Enzymology, Vol. 86. Lands, W.E.M. & Smith, W.L. (eds) pp. 202–209, New York: Academic Press.Google Scholar
  12. HUNG, S.C., GHALI, N.I., VENTON, D.L. & LE BRETON, G.C. (1983). Specific binding of the thromboxane A2 antagonist 13-azaprostanoic acid to human platelet membranes. Biochim. biophys. Acta, 728, 171–178.CrossRefGoogle Scholar
  13. JONES, R.L. (1976). Sites of action of prostaglandins on the cardiovascular system with particular reference to the sheep. Acta biol. med. germ., 35, 1091–1096.Google Scholar
  14. JONES, R.L. (1978). Definition of prostaglandin-sensitive arterial constrictor systems. Acta biol. med. germ., 37, 837–844.Google Scholar
  15. JONES, R.L., PEESAPATI, V. & WILSON, N.H. (1982). Antagonism of the thromboxane-sensitive contractile systems of the rabbit aorta, dog saphenous vein and guinea-pig trachea. Br. J. Pharmac, 76, 423–438.CrossRefGoogle Scholar
  16. KENNEDY, I., COLEMAN, R.A., HUMPHREY, P.P.A. & LUMLEY, P. (1983). Studies on the characterization of prostanoid receptors. In Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 11. Samuelsson, B., Paoletti, R. & Ramwell, P. (eds) pp. 327–332, New York: Raven Press.Google Scholar
  17. KIMBALL, F.A. & WYNGARDEN, L.J. (1977). Prostaglandin F2a specific binding in equine corpora lutea. Prostaglandins, 13, 553–564.CrossRefGoogle Scholar
  18. KUEHL, F.A. (1976). Prostaglandin receptors. In Hormone Receptor Interaction: Molecular Aspects. Levey, G.S. (ed.) pp. 385–400, New York: Marcel Dekker, Inc.Google Scholar
  19. LEFER, A.M., SMITH, E.F.III, ARAKI, H., SMITH, J.B., AHARONY, D., CLAREMON, D.A., MAGOLDA, R.L. & NICOLAOU, K.C. (1980). Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc. natn. Acad. Sei., U.S.A., 77, 1706–1710.CrossRefGoogle Scholar
  20. MacDERMOT, J., BARNES, P.J., WADDELL, K.A, DOLLERY, C.T. & BLAIR, LA. (1981). Prostacyclin binding to guinea-pig pulmonary receptors. Eur. J. Pharmac, 75, 127–130.CrossRefGoogle Scholar
  21. MACINTYRE, D.E. (1981). Platelet prostaglandin receptors. In Platelets in Biology and Pathology (Research Monographs in Cell & Tissue Physiology, Vol. 2). MACINTYRE, D.E, (ed.) pp. 211–246. Elsevier.Google Scholar
  22. MADDOX, Y.T., RAMWELL, P.W., SHINER, CS. & COREY, E.J. (1978). Amide and 1-amino derivatives of F prostaglandins as prostaglandin antagonists. Nature, 273, 549–552.CrossRefGoogle Scholar
  23. MAIN, LH.M. (1964). The inhibitory action of prostaglandins on respiratory smooth muscle. Br. J. Pharmac. Chemother., 22, 511–519.CrossRefGoogle Scholar
  24. MILLER, O.V. & GORMAN, R.R. (1979). Evidence for distinct prostaglandin I2 and E receptors in human platelets. J. Pharmac. exp. Ther., 210, 134–140.Google Scholar
  25. NICOLAOU, K.C., BARNETTE, W.E. & MAGOLDA, R.L. (1980). Synthesis and biological properties of prostacyclins. In Prostaglandins in Cardiovascular and Renal Function. Scriabine, A., Lefer, A.M. & Kuehl, F.A. (eds), pp. 9–28, New York: Spectrum Publications Inc.Google Scholar
  26. NICOLAOU, K.C., MAGOLDA, R.L., SMITH, J.B., AHARONY, D., SMITH, E.F. & LEFER, A.M. (1979). Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation and thromboxane formation. Proc. natn. Acad. Sei. U.S.A, 16, 2566–2570.CrossRefGoogle Scholar
  27. POSNER, J. (1973). Prostaglandin E2 and the bovine sphincter pupillae. Br. J. Pharmac., 49, 415–427.CrossRefGoogle Scholar
  28. POYSER, N.L. (1981a). Uterine prostaglandins in luteolysis and menstruation. In Prostaglandins in Reproduction, pp. 83–143. New York: John Wiley & Sons Ltd.Google Scholar
  29. POYSER, N.L. (1981b). Applied aspects. In Prostaglandins in Reproduction, pp. 233–254, New York: John Wiley & Sons Ltd.Google Scholar
  30. RAO, C.V. & MITRA, S.B. (1982). Distribution of PGE and PGF2a receptor proteins in the intracellular organelles of bovine corpora lutea. In Methods in Enzymology, Vol. 86. Lands, W.E.M. & Smith, W.L. (eds) pp. 192–202, New York: Academic Press.Google Scholar
  31. RÜCKER, W. & SCHRÖR, K. (1983). Evidence for high affinity prostacyclin binding sites in vascular tissue: radioligand studies with a chemically stable analogue. Biochem. Pharmac, 32, 2405–2410.CrossRefGoogle Scholar
  32. SANNER, J.H. (1969). Antagonism of prostaglandin E2 by l-acetyl-2-(8-chloro-10,11-dihydrodibenz [b ,f] [1,4] oxazepine-10-carbonyl) hydrazine (SC-19220). Arch. Int. Pharmacodyn. Ther., 180, 46–56.Google Scholar
  33. SCHILLINGER, E. & PRIOR, G. (1980). Prostaglandin I2 receptors in a particulate fraction of platelets of various species. Biochem. Pharmac, 29, 2297–2299.CrossRefGoogle Scholar
  34. SCHRÖR, K., DARIUS, H., MATZKY, R. & OHLENDORF, R. (1981). The anti-platelet and cardiovascular actions of a new carbacyclin derivative (ZK 36374) — equipotent to PGI2 in vitro. Naunyn-Schmiedeberg’s Arch. Pharmac., 316, 252–255.CrossRefGoogle Scholar
  35. SIEGL, A.M. (1982). Receptors for PGI2 and PGD2 on human platelets. In Methods in Enzymology, Vol. 86. Lands, W.E.M. & Smith, W.L. (eds) pp. 179–191, New York: Academic Press.Google Scholar
  36. STINGER, R.B., FITZPATRICK, T.M., COREY, E.J., RAM-WELL, P.W., ROSE, J.C. & KOT, P.A. (1982). Selective antagonism of prostaglandin F2a mediated vascular responses by N-dimethylamine substitution of prostaglandin F2a. J. Pharmac. exp. Ther., 220, 521–525.Google Scholar
  37. TOWN, M.-H., SCHILLINGER, E., SPECKENBACH, A. & PRIOR, G. (1982). Identification and characterisation of a prostacyclin-like receptor in bovine coronary arteries using a specific and stable prostacyclin analogue, ciloprost, as radioactive ligand. Prostaglandins, 24, 61–72.CrossRefGoogle Scholar
  38. WELBURN, P.J. & JONES, R.L. (1978). A comparison of prostaglandin F2a and three 16-aryloxy analogues on the isolated rabbit jejunum. Prostaglandins, 15, 287–296.CrossRefGoogle Scholar
  39. WHITTLE, B.J.R., MONCADA, S. & VANE, J.R. (1978). Comparison of the effects of prostacyclin (PGI2), prostaglandin E 1 and D2 on platelet aggregation in different species. Prostaglandins, 16, 373–388.CrossRefGoogle Scholar

Copyright information

© Macmillan Publishers Limited 1984

Authors and Affiliations

  • R. L. Jones
    • 1
  • N. H. Wilson
    • 1
  • R. A. Armstrong
    • 1
  • Y. J. Dong
    • 1
  1. 1.Department of PharmacologyUniversity of EdinburghEdinburghUK

Personalised recommendations